Sengine Precision Medicine Inc. boosted its total fundraising to $19 million with the recent closing of a $10 million series A2 led by the Washington Research Foundation with support from Alethea Fulcrum Fund, Vincere Capital Biotech LLC, Bangarang Group and others. The A2 follows on an earlier $5 million raised in the original series A. Sengine’s Paris Test predicts drug responses using a patient’s cancer cells to grow a tumor organoid that replicates the functionality and genomic characteristics of the original tumor, enabling hyper-personalization of cancer treatment.

Oricell Therapeutics Co. Ltd. has raised $120 million in a series B financing to support development of its cell therapy pipeline and technology platform, as well as the construction of a manufacturing plant. The round was jointly led by Qiming Venture Partners and Quan Capital Management LLC.

Structure Therapeutics Inc. raised $33 million in a financing round to speed up clinical trials of its lead assets targeting chronic diseases and to improve its technology platform. Previously known as Shouti Inc., the company also has rebranded itself as Structure to “reflect its foundation in structural biology and computational design.”

F2G Ltd. has raised a further $70 million in venture capital as it continues preparations to submit a new drug application to the U.S. FDA for its novel antifungal drug, olorofim, before the end of 2022.

The amount of money raised by biopharma companies so far this year is down by 59% in comparison with last year, and there are 42% fewer transactions.